MediWound is a biopharmaceutical company focused on developing enzymatic therapeutics for non-surgical tissue repair. It specializes in biologics that improve standards of care in the treatment of severe thermal burns and chronic wounds, self-described as a leader in this field.

MediWound

MediWound | 4,242 followers on LinkedIn. The global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair | MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care, the Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries.

CEO at Clal Biotechnology (CBI)

Assaf Segal

Eva Sharon, PharmD

Eva Sharon

Quality Assurance Project Manager at MediWound Ltd.

Galia Ozerov

Advising and supporting Life Science innovation

Samuel Moed

🌟 New Publication in the Journal of Clinical Medicine (JCM) MDPI 🌟 We’re excited to share MediWound’s latest research on an innovative approach to treating Basal Cell Carcinoma (BCC) with MW005—a bromelain-enriched topical enzymatic treatment derived from pineapple stems. 🔍 Highlights: • Proof-of-concept studies on 22 BCC cases demonstrated effective tumor removal, rapid healing, and no scarring. • This next-generation, non-invasive treatment offers a promising alternative to surgical and non-surgical treatments of low-risk BCC, the most common human cancer. 📖 Read the publication here: https://lnkd.in/d2zNMQzc Yaron Shoham Lior Rosenberg #BCC #JournalOfClinicalMedicine #Oncology #ClinicalResearch #SkinCancerCare #InnovationInHealthcare

We are honored to have sponsored the European Burns Association (EBA) 3rd Educational Course in Porto! We're proud to be part of a community that’s so dedicated to improving patient outcomes and advancing medical knowledge. #EBA #BurnCare #MedicalEducation

🌟 Employee Spotlight of the Month: Menachem Saraf 🌟 This month, we’re excited to feature menachem saraf , our dedicated R&D Production & Development Supporter here at MediWound. While his title may hint at his role, Menachem does so much more. With over two years at MediWound, he has been pivotal in advancing EscharEx production and supporting MTEC trials and development. Having previously worked with TEVA Pharmaceuticals, Menachem brings a wealth of experience and dedication to our mission. Beyond his work, Menachem’s passions include sports, running, martial arts, and traveling. A family man with one child and another on the way, he values MediWound's family-oriented culture and embodies the spirit that “the more you give, the more you gain.” His professional growth here has been phenomenal, and he finds special meaning in supporting a company dedicated to developing life-saving treatments—especially for soldiers, a cause close to his heart as a former combat soldier in the IDF. Menachem’s enthusiasm and positive energy uplift our team every day. His warm smile and unyielding professionalism remind us of the value of community, purpose, and passion in the workplace. We are truly lucky to have him with us at MediWound. Thank you, Menachem, for your commitment and for inspiring us all! #MediWoundFamily #EmployeeSpotlight #LifeSavingInnovation

🚨 Join Us at EBA 2024 in Porto, Portugal – October 17-18, 2024! 🚨 MediWound is honored to be a Platinum Sponsor at this year’s European Burns Association (EBA) Congress. We invite you to meet our team and attend two exclusive workshops on Thursday, October 17: 🔹 Enzymatic Debridement with NexoBrid – The Practice 🔹 Burn Mass Casualty Incident and Medical Countermeasures We are excited to connect, share knowledge, and collaborate with professionals in the field. Let’s make a difference together! 📅 To schedule a meeting with us, please contact Torrenova Alicia or Alberto Alabastro . #EBA2024 #BurnCare #NexoBrid #EnzymaticDebridement #BurnMassCasualty #MedicalCountermeasures #PortoPortugal

🚀 We're Hiring! Pilot Operator - MS&T Team 🚀 Join our dynamic MS&T team (Manufacturing Science & Technology) and play a key role in bringing development solutions to life. We’re looking for a motivated and skilled Pilot Operator to support our manufacturing and scale-up projects. If you’re passionate about development and eager to be part of a team that’s pushing the boundaries of what's possible, we want to hear from you! Apply now: https://lnkd.in/dmb9q5iY Or tag someone who might be interested!

We're thrilled to announce our Phase II head-to-head study evaluating #EscharEx ® versus collagenase ointment for treating venous leg ulcers (VLUs). This study will support EscharEx’s Biologics License Application (BLA) submission and will strengthen our commercialization strategy. In addition, we’re proud to have secured additional R&D collaborations with Solventum and Mölnlycke Health Care ensuring consistent trial quality and enhanced patient outcomes. As we advance the field of enzymatic debridement, we remain confident in EscharEx’s potential to address clinical unmet needs for patients with chronic wounds. Learn more: https://lnkd.in/dXe4Wfmv #ClinicalTrials #WoundCare #Biologics #HealthcareInnovation #EnzymaticTherapeutics #VLUs

We are excited to share a recent interview with Drug Development & Delivery , where Ofer Gonen , our CEO, provides insights into MediWound’s innovative approach to enzymatic debridement, the development of our breakthrough drug NexoBrid®, and our expanding pipeline, including EscharEx® for chronic wounds. Stay tuned as we continue to push the boundaries in wound care and develop solutions that make a real difference in patients’ lives! FINN Partners FINN Partners Israel #InnovationInHealthcare #WoundCare #Biologics #NexoBrid #EscharEx #HealthcareTransformation

We are pleased to announce that our CEO, Ofer Gonen , will be participating in a fireside chat at the 2024 Maxim Group LLC Healthcare Virtual Summit. The discussion, hosted by Michael Okunewitch , Senior Biotechnology Analyst at Maxim, will take place on Wednesday, October 16, 2024, at 9:30 a.m. ET. Learn more: https://lnkd.in/dpe_Qneq #Healthcare #MaximHealthcareSummit #TissueRepair #Biotechnology

We are proud to have been a sponsor of the XVII Congress of the Polish Burn Treatment Society, held from October 3-5 in beautiful Stare Jabłonki! This annual conference brings together experts in burn treatment, including surgeons, plastic surgeons, nurses, and key representatives from leading medical units. It is always an honor to be part of such an important event, where burn care advancements and best practices are shared to improve patient outcomes. At MediWound, we are committed to supporting the burn care community and collaborating with professionals dedicated to innovative and effective burn treatments. Robert Liss Torrenova Alicia #BurnCare #BurnTreatment #Poland #PolishBurnTreatmentSociety

Wishing You a Happy, Healthy, and Sweet New Year! As we welcome Rosh Hashanah, the Jewish New Year, we at MediWound would like to extend our warmest wishes to our colleagues, partners, and friends around the world. May this year bring you and your loved ones health, happiness, and prosperity. Shana Tova U'Metuka! 🌟 #RoshHashanah #ShanaTova #HappyNewYear #Health #Innovation

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

COM:MEDIWOUND

MediWound

Last Close

16.78

21/11 21:00

Market Cap

176.11M

Beta: -

Volume Today

44.68K

Avg: -

Filings Not Available